Director, President and Head of R&D · Taysha Gene Therapies, Inc. · Taysha Gene Therapies, Inc. — Employee Stock Option (right to buy)
Side
M
Value
—
Shares
19.0K
Price
—
Executed
Apr 10, 2026
Disclosed
Apr 13, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Apr 10 executedApr 13, 2026 disclosed
TSHA · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
No reported dollar value · 4.4% of prior position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
3 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Taysha Gene Therapies, Inc. — Employee Stock Option (right to buy)
Ticker
TSHA
Shares
19.0K
Price per share
$0
Execution date (reported)
Apr 10, 2026
Owned after transaction
455.9K shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
3
What this establishes
Nagendran Sukumar filed this Form 4 reporting a option exercise of TSHA on Apr 10, 2026. It became public on Apr 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, President and Head of R&D
Nagendran Sukumarcik:0001665124
Issuer
Taysha Gene Therapies, Inc.cik:0001806310
Revision history · 0
No field has changed since this record was first ingested.
